Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer

Table 1 Correlation between p53 and mdm2 expression and clinicopathological parameters.

Parameters		No. of patients(n = 59)	Number expressing (%)
			p53(+) (n = 40)	mdm2(+) (n = 17)
Gender	Male	38	25 (65.8)	10 (26.3)
	Female	21	15 (71.4)	7 (33.3)
Age (yr)	<65	47	35 (74.5)	13 (27.7)
	≥65	12	5 (41.7)	4 (33.3)
Site	Head	52	34 (65.4)	16 (30.8)
	Body/tail	7	6 (85.7)	1 (14.3)
TNM stage	I	4	2 (50)	0 (0)
	II	8	4 (50)	0 (0)
	III	42	34 (81)	15 (35.7)
	IV	5	4 (80)	2 (40)
Grade	Well	19	14 (73.7)	4 (21.1)
	Moderate	21	12 (57.1)	9 (42.9)
	Poor	19	14 (73.7)	4 (21.1)

Table 2 Correlation between p53 and mdm2 expression and prognosis.

Protein expression	No. of patients	Median survival (mo)
p53(+)	40	6.2
p53(-)	19	10.3
mdm2(+)	17	6.8
mdm2(-)	42	12.1
p53(+)mdm2(+)	15	7.41
p53(+)mdm2(-)	25	13.51
p53(-) mdm2(+)	2	9.21
p53(-) mdm2(-)	17	12.81

¹Group comparison was performed by log-rank test (χ² = 11, P = 0.012).

Table 3 Correlation between various factors and survival time by Cox proportional hazards model (dependent variable, mo; censoring variable, death due to pancreatic cancer).

Variable	Parameter estimate (SE)	Conditional risk ratio (95% confidence limits)	P (χ2)
mdm2	0.969 (0.324)	2.636 (1.397-4.975)	0.003
Age (yr)	0.210 (0.013)	1.021 (0.996-1.047)	0.101
TNM	0.279 (0.223)	1.322 (0.853-2.048)	0.212
Grade	0.207 (0.193)	1.229 (0.842-1.795)	0.285
Site	-0.468 (0.469)	0.627 (0.250-1.570)	0.318
p53	0.336 (0.345)	1.399 (0.712-2.751)	0.330
Gender	-0.010 (0.352)	0.990 (0.496-1.974)	0.977